These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3104711)

  • 1. Administration of an LHRH-antagonist to male mice: effects on in vivo secretion of hormones and on the growth of a transplantable human prostatic carcinoma.
    van Steenbrugge GJ; Ultee-van Gessel AM; Groen M; de Jong FH; Schroeder FH
    Life Sci; 1987 Mar; 40(13):1335-43. PubMed ID: 3104711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of plasma gonadotropins and testosterone in adult male monkeys (Macaca fascicularis) by a potent inhibitory analog of gonadotropin-releasing hormone.
    Adams LA; Bremner WJ; Nestor JJ; Vickery BH; Steiner RA
    J Clin Endocrinol Metab; 1986 Jan; 62(1):58-63. PubMed ID: 3079603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compensatory response of the luteinizing-hormone (LH)-releasing hormone (LHRH)/LH pulse generator after administration of a potent LHRH antagonist in the ram.
    Lincoln GA; Fraser HM
    Endocrinology; 1987 Jun; 120(6):2245-50. PubMed ID: 3032581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists.
    Redding TW; Schally AV
    J Endocrinol; 1990 Aug; 126(2):309-15. PubMed ID: 2144873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone.
    Redding TW; Coy DH; Schally AV
    Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1273-6. PubMed ID: 6803239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of serum luteinizing hormone and testosterone with an inhibitory analog of luteinizing hormone-releasing hormone in adult male rhesus monkeys.
    Burgos-Briceño LA; Schally AV; Bartke A; Asch RH
    J Clin Endocrinol Metab; 1984 Oct; 59(4):601-7. PubMed ID: 6384248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6509-12. PubMed ID: 6458815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.
    Pavlou SN; Debold CR; Island DP; Wakefield G; Rivier J; Vale W; Rabin D
    J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifertility effects of a potent LH-RH antagonist in male and female rats.
    Debeljuk L; Schally AV
    Int J Fertil; 1986; 31(4):284-92. PubMed ID: 2878898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropins and testosterone escape from suppression during prolonged luteinizing hormone-releasing hormone antagonist administration in normal men.
    Pavlou SN; Interlandi JW; Wakefield G; Island DP; Rivier J; Vale W; Kovacs WJ
    J Clin Endocrinol Metab; 1987 May; 64(5):1070-4. PubMed ID: 3104387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
    Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
    Bokser L; Srkalovic G; Szepeshazi K; Schally AV
    Neuroendocrinology; 1991 Aug; 54(2):136-45. PubMed ID: 1662786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield GB; Island DP; Hoffman PG; LePage ME; Chan RL; Nerenberg CA; Kovacs WJ
    J Clin Endocrinol Metab; 1987 May; 64(5):931-6. PubMed ID: 3104388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
    Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
    Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo administration of a GnRH antagonist to male mice: effects on pituitary gonadotropin secretion in vitro.
    Ultee-van Gessel AM; van Steenbrugge GJ; Leemborg FG; Schroeder FH; de Jong FH
    Acta Endocrinol (Copenh); 1989 Mar; 120(3):308-14. PubMed ID: 2494824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.